Editor: Peter Timms
Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung
Article first published online: 5 JAN 2009
© 2009 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved
FEMS Immunology & Medical Microbiology
Volume 55, Issue 3, pages 346–351, April 2009
How to Cite
Arévalo, M. T., Xu, Q., Paton, J. C., Hollingshead, S. K., Pichichero, M. E., Briles, D. E., Girgis, N. and Zeng, M. (2009), Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunology & Medical Microbiology, 55: 346–351. doi: 10.1111/j.1574-695X.2008.00518.x
- Issue published online: 9 MAR 2009
- Article first published online: 5 JAN 2009
- Received 21 October 2008; revised 27 November 2008; accepted 27 November 2008.First published online 05 January 2009.
- mucosal vaccination;
- pneumococcal vaccine;
- protective immunity;
- replication-defective adenovirus;
- Streptococcus pneumoniae.
Streptococcus pneumoniae is a major bacterial respiratory pathogen. Current licensed pneumococcal polysaccharide and polysaccharide–protein conjugate vaccines are administered by an intramuscular injection. In order to develop a new-generation vaccine that can be administered in a needle-free mucosal manner, we have constructed early 1 and 3 gene regions (E1/E3) deleted, replication-defective adenoviral vectors encoding pneumococcal surface antigen A (PsaA), the N-fragment of pneumococcal surface protein A (N-PspA), and the detoxified mutant pneumolysin (PdB) from S. pneumoniae strain D39. Intranasal vaccination with the three adenoviral vectors (Ad/PsaA, Ad/N-PspA, and Ad/PdB) in mice resulted in robust antigen-specific serum immunoglobulin G responses, as demonstrated by an enzyme-linked immunosorbent assay. In addition, nasal mucosal vaccination with the combination of the three adenoviral vectors conferred protection against S. pneumoniae strain D39 colonization in mouse lungs. Taken together, these data demonstrate the feasibility of developing a mucosal vaccine against S. pneumoniae using recombinant adenoviruses for antigen delivery.